Optimal management of digital ulcers in systemic sclerosis

References

• DentonCPKornJHDigital ulceration and critical digital ischaemia in sclerodermaScleroderma Care Res200311216
   Google Scholar
• BaronMConsensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosisClin Rheumatol201433220721424357325
   PubMed Web of Science ®Google Scholar
• SunderkotterCHergottIBrucknerCComparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factorsBr J Dermatol200916083584319183180
   PubMed Web of Science ®Google Scholar
• HachullaEClersonPLaunayDNatural history of ischemic digital ulcers in systemic sclerosis: a single-center retrospective longitudinal studyJ Rheumatol2007342423243017985402
   PubMed Web of Science ®Google Scholar
• SteenVDentonCPPopeJEMatucci-CerinicMDigital ulcers: overt vascular disease in systemic sclerosisRheumatology2009481924
   Web of Science ®Google Scholar
• FerriCSebastianiMLo MonacoSystemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients’ population and review of the literatureAutoimmun Rev201413101026103410.1016/j.autrev.2014.08.02925182204
   PubMed Web of Science ®Google Scholar
• ThompsonAEPopeJECalcium channel blockers for primary Raynaud’s phenomenon: a meta-analysisRheumatology20054414515015546967
   PubMed Web of Science ®Google Scholar
• BotzorisVDrososAAManagement of Raynaud’s phenomenon and digital ulcers in systemic sclerosisJoint Bone Spine201178434134621183379
   PubMed Web of Science ®Google Scholar
• HughesJLockhartJJoyceADo calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest painBr J Clin Pharmacol2007641838917298478
   PubMed Web of Science ®Google Scholar
• GoreJSilverROral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosisAnn Rheum Dis2005649138716100356
   PubMed Web of Science ®Google Scholar
• KumarKGriffithsBAllenJThermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud’s phenomenon in patients with systemic sclerosis: a potential treatmentJ Rheumatol20063391918191916960964
   PubMed Web of Science ®Google Scholar
• FriesRShariatKVon WilmowskyHBohmMSildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapyCirculation2005112192980298516275885
   PubMed Web of Science ®Google Scholar
• BruecknerCSBeckerMOKroenckeTEffect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot studyAnn Rheum Dis20106981475147819900936
   PubMed Web of Science ®Google Scholar
• CaglayanEHuntgeburthMKaraschTPhosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud’s diseaseArch Intern Med2006166223123316432094
   PubMedGoogle Scholar
• CarlinoGTreatment of Raynaud’s phenomenon with tadalafil, a phosphodiesterase-5 inhibitor (abstract)Ann Rheum Dis200564258
   Web of Science ®Google Scholar
• SchiopuEHsuVMImpensAJRandomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosisJ Rheumatol200936102264226819755613
   PubMed Web of Science ®Google Scholar
• RosatoELetiziaCProiettiMPlasma adrenomedullin and endothelin-1 levels are reduced and Raynaud’s phenomenon improved by daily tadalafil administration in male patients with systemic sclerosisJ Biol Regul Homeost Agents2009231232919321043
   PubMed Web of Science ®Google Scholar
• ShenoyPDKumarSJhaLKEfficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double blind randomized cross over trialRheumatology201049122420242820837499
   PubMed Web of Science ®Google Scholar
• AgarwalVGhoshPSharmaAEfficacy of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis: a double blind randomized placebo controlled parallel group multicenter studyArthritis Rheum201062S872
   Google Scholar
• LeeEYParkJKLeeWHead-to-head comparison of udenafil versus amlodipine in the treatment of secondary Raynaud’s phenomenon: a double-blind, randomized, cross-over studyRheumatology (Oxford)201453465866424352340
   PubMed Web of Science ®Google Scholar
• RoustitMBlaiseSAllanoreYCarpentierPHCaglayanECracowskiJLPhosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trialsAnn Rheum Dis201372101696169923426043
   PubMed Web of Science ®Google Scholar
• WigleyFMWiseRASeiboldJRIntravenous iloprost infusions in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind studyAnn Intern Med19941201992067506013
   PubMed Web of Science ®Google Scholar
• BadeschDTapsonVMcGoonMContinuous intravenous epoprostenol for pulmonary hypertension due to scleroderma spectrum of diseaseAnn Intern Med200013242543410733441
   PubMed Web of Science ®Google Scholar
• WigleyFMKornJHCsukaMEOral iloprost treatment in patients with Raynaud phenomenon secondary to systemic sclerosis: a multi-center, placebo-controlled, double-blind studyArthritis Rheum1998416706779550476
   PubMed Web of Science ®Google Scholar
• ShahAASchiopuEHummersLKRetrospective look at the recurrence of digital ulcers in patients with scleroderma after discontinuation of oral treprostinilArthritis Rheum201566S848
   Web of Science ®Google Scholar
• Garcia de la Pena-LefebvrePRodriguez RubioSValero ExpositioMLong term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patientsRheumatology (Oxford)20084746446618263597
   PubMed Web of Science ®Google Scholar
• KornJHMayesMMatucci CerinicMDigital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonistArthritis Rheum2004503985399315593188
   PubMed Web of Science ®Google Scholar
• SeiboldJRDentonCPFurstDEBosentan prevents occurrence but does not speed healing of digital ulcers in patients with systemic sclerosis (SSc)Arthritis Rheum2005524057
   Google Scholar
• AndersonMEMooreTLHollisSJaysonMIVKingTAHerrickALDigital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosisRheumatology200241332432811934971
   PubMed Web of Science ®Google Scholar
• ChungLShapiroLFiorentinoDMQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized controlled trialArthritis Rheum20096087087719248104
   PubMed Web of Science ®Google Scholar
• HummersLKDugowsonCEDechowFA multi-centre, blinded, randomized, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenonAnn Rheum Dis2013721962196723268365
   PubMed Web of Science ®Google Scholar
• TehLSManningJMooreTTullyMPO’ReillyDJaysonMIVSustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenonBr J Rheumatol1995346366417670782
   PubMedGoogle Scholar
• SamboPAmicoDGiacomelliRIntravenous N-acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a pilot studyJ Rheumatol200128102257226211669166
   PubMed Web of Science ®Google Scholar
• RosatoEBorgheseFPisarriSThe treatment with N-acetylcysteine of Raynaud’s phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patientsClin Rheumatol200928121379138419690939
   PubMed Web of Science ®Google Scholar
• DziadzioMDentonCPSmithRLosartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trialArthritis Rheum1999422646265510616013
   PubMed Web of Science ®Google Scholar
• PopeJFenlonDThompsonAPrazosin for Raynaud’s phenomenon in progressive systemic sclerosisCochrane Database Syst Rev20002CD00095610796398
   PubMedGoogle Scholar
• ColeiroBMarshallSEDentonCPTreatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetineRheumatology2001401038104311561116
   PubMed Web of Science ®Google Scholar
• Abou-RayaAAbou-RayaSHelmiiMStatins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcersJ Rheumatol2008351801180818709692
   PubMed Web of Science ®Google Scholar
• FioriGGalluccioFBraschiFVitamin E gel reduces time of healing of digital ulcers in systemic sclerosisClin Exp Rheumatol2009273515419796562
   PubMed Web of Science ®Google Scholar
• MoranMEScleroderma and evidence based non-pharmaceutical treatment modalities for digital ulcers: a systematic reviewJ Wound Care2014231051051625296352
   PubMed Web of Science ®Google Scholar
• MatsumotoYUeyamaTEndoMEndoscopic thoracic sympathectomy for Raynaud’s phenomenonJ Vasc Surg2002361576112096258
   PubMed Web of Science ®Google Scholar
• WassermanABrahnESystemic sclerosis: bilateral improvement of Raynaud’s phenomenon with unilateral digital sympathectomySemin Arthritis Rheum20104013714619878974
   PubMed Web of Science ®Google Scholar
• RuchDSHoldenMSmithBPPeriarterial sympathectomy for treatment of chronic digital ischemiaJ Rheumatol20033081788179212913936
   PubMed Web of Science ®Google Scholar
• MomeniASoriceSValenzuelaASurgical treatment of systemic sclerosis – is it justified to offer peripheral sympathectomy earlier in the disease process?Microsurgery Epub201511410.1002/micr.22379
   Web of Science ®Google Scholar
• UppalLDhaliwalKButlerPEA prospective study of the use of botulinum toxin injections in the treatment of Raynaud’s syndrome associated with sclerodermaJ Hand Surg201439876880
   Web of Science ®Google Scholar
• IorioMMasdenDHigginsJBotulinum toxin a treatment of Raynaud’s phenomenon: a reviewSemin Arthritis Rheum20124159960321868066
   PubMed Web of Science ®Google Scholar
• GranelBDaumasAJouveESafety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase 1 trialAnn Rheum Dis Epub201481110.1136/annrheumdis-2014-205681
   PubMed Web of Science ®Google Scholar
• Del BeneMDPozziMRRovatiLAutologous fat grafting for scleroderma-induced digital ulcers. An effective technique in patients with systemic sclerosisHandchir Mikrochir Plast Chir20144624224725162242
   PubMed Web of Science ®Google Scholar
• TaylorMHMcFaddenJABolsterMBUlnar artery involvement in systemic sclerosis (scleroderma)J Rheumatol200229110210611824945
   PubMed Web of Science ®Google Scholar